SAN DIEGO, Aug. 31 /PRNewswire/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced the election of Jay S. Skyler, MD to its Board
of Directors. Dr. Skyler will assume his position on the board effective
immediately.
Dr. Skyler is Professor of Medicine, Pediatrics, and Psychology and
Co-Director of the Behavioral Medicine Research Center at the University of
Miami in Florida. He is also Director of the Operations Coordinating Center
for the NIDDK's (National Institute of Diabetes & Digestive & Kidney Diseases)
Diabetes Prevention Trial in Type 1 Diabetes. Dr. Skyler has served as
President of the American Diabetes Association, and is current Vice President
of the International Diabetes Federation. Dr. Skyler is a member of the
Florida Governor's Diabetes Advisory Council, and serves on the Editorial
Board of several diabetes and general medicine journals. He received a doctor
of medicine degree from Jefferson Medical College, and completed postdoctoral
studies at Duke University Medical Center.
"I welcome the opportunity to help guide Amylin's exciting research and
development programs," commented Dr. Skyler. "Diabetes affects the lives of
millions of people, and has serious medical consequences. Research leading to
therapeutic improvements in the management of diabetes and related metabolic
disorders would be of great benefit."
"I am delighted that Jay Skyler has agreed to join our board," said Joseph
C. Cook, Jr., Amylin's Chairman and Chief Executive Officer. "Jay's extensive
knowledge and experience in diabetes research and clinical practice will be a
tremendous asset as the company moves forward."
Amylin Pharmaceuticals, Inc. is a development pharmaceutical company
focused on metabolic disorders, and specializing in preclinical
characterization of lead molecules and demonstration of proof of principle in
humans. The Company has pioneered research of the hormone amylin and is
developing SYMLIN(TM) (pramlintide acetate), a synthetic analog of human
amylin, for the treatment of diabetes in people using insulin. The results of
the Company's ongoing one-year Phase 3, US study of SYMLIN in type 1 diabetes
are planned to be reported in the fourth quarter of this year. AC2993
(synthetic exendin-4), the Company's second diabetes drug candidate, is being
evaluated in type 2 diabetes and related metabolic disorders. The Company has
successfully completed a Phase 1 safety and tolerability trial and a clinical
study of AC2993 in people with type 2 diabetes. A Phase 2, multiple-dose
study in people with type 2 diabetes is currently in progress. The Company
has demonstrated that AC2993 is biologically active in animal models when
administered via noninjectable routes. The Company is currently engaged in
partnership discussions for SYMLIN and AC2993. Amylin Pharmaceuticals is
headquartered in San Diego, California. Further information on the Company
and its development pipeline is available at amylin.com. |
